Sign up to save your podcasts
Or
Share A New Sickle Cell Disease Treatment
Share to email
Share to Facebook
Share to X
Share to email
Share to Facebook
Share to X
Or
A New Sickle Cell Disease Treatment
Photo by National Cancer Institute on Unsplash
Last Friday the FDA approved the world’s first medicine based on CRISPR gene-editing technology, a groundbreaking treatment for sickle cell disease that delivers a potential cure for people born with the chronic and life-shortening blood disorder.
Dr. Dora Clayton- Jones is an Associate Professor, at Marquette University College of Nursing, a Board Member of the, International Association of Sickle Cell Nurses and Professional Associates, and a U C Davis Fellow, Betty Irene Moore Fellowships for Nurse Leaders and Innovators One of her areas of expertise is focusing on transitions of care for adolescents living with sickle cell disease. She is committed to eliminating sickle cell disparities among youth.
View all episodes
By HealthCetera, HealthCetera podcast by Senior Producers Diana J. Mason and Barbara Glickstein
5
77 ratings
Photo by National Cancer Institute on Unsplash
Last Friday the FDA approved the world’s first medicine based on CRISPR gene-editing technology, a groundbreaking treatment for sickle cell disease that delivers a potential cure for people born with the chronic and life-shortening blood disorder.
Dr. Dora Clayton- Jones is an Associate Professor, at Marquette University College of Nursing, a Board Member of the, International Association of Sickle Cell Nurses and Professional Associates, and a U C Davis Fellow, Betty Irene Moore Fellowships for Nurse Leaders and Innovators One of her areas of expertise is focusing on transitions of care for adolescents living with sickle cell disease. She is committed to eliminating sickle cell disparities among youth.